ClinicalTrials.gg
CompletedNCT04412863Updated Apr 16, 2026Results posted

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

A Phase 2 interventional study of VIR-2218 and pegylated interferon-alfa 2a in Chronic Hepatitis B, sponsored by Vir Biotechnology, Inc.. Completed at 22 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Vir Biotechnology, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Hepatitis B, Chronic with a site in Thailand — 3 open to participants now, 3 under way, none of them phase 3. Hepatitis B, Chronic · Thailand.

Enrollment
30th of 41
84 · median 126
Started
2020
with 3 others
Phase 2
12 of 51
none open now
Registered
35th of 51
by date
Lead sponsor
2 of 51
Vir Biotechnology, Inc.

Among the 51 studies in Hepatitis B, Chronic with a site in Thailand, this one is the 30th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2020, is one of 12 in phase 2, and was the 35th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 51 studies in Hepatitis B, Chronic with a site in Thailand are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hepatitis B, Chronic with a site in Thailand, or all of them as a file.
02

Study summary

This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • Hepatitis B Virus
  • Chronic Hepatitis B
  • HBV
  • Hepatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of ages 18 - 65
  • Chronic infection for >/= 6 months

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the volunteer unsuitable for participation
  • Significant fibrosis or cirrhosis
  • History or evidence of drug or alcohol abuse
  • History of intolerance to SC injection
  • History of chronic liver disease from any cause other than chronic infection
  • History of hepatic decompensation
  • Any prior receipt of an interferon product
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Cohort 1d

    VIR-2218 given by subcutaneous injection

    Drug: VIR-2218

  • Experimental
    Cohort 2d

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

  • Experimental
    Cohort 3d

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

  • Experimental
    Cohort 1e

    VIR-2218 given by subcutaneous injection

    Drug: VIR-2218

  • Experimental
    Cohort 2e

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

  • Experimental
    Cohort 3e

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

  • Experimental
    Cohort 1f

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

  • Experimental
    Cohort 2f

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

  • Experimental
    Cohort 3f

    VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection

    Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a

Interventions

  • VIR-2218 given by subcutaneous injection

    Also known as: Elebsiran

  • pegylated interferon-alfa 2a given by subcutaneous injection

    Also known as: pegylated interferon alpha-2a, PEG-IFNα

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events as Assessed by CTCAE v5.0

    Time frame: Up to 148 Weeks

  2. Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings

    Time frame: Up to 148 Weeks

Secondary outcomes

  1. Mean Maximum Reduction of Serum HBsAg at Any Timepoint

    Time frame: Up to 148 Weeks

  2. Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint

    Time frame: Up to 148 Weeks

  3. Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months

    Time frame: Up to 148 Weeks

  4. Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint

    Anti-HBs seroconversion is defined as Anti-HBs quantitative value changed from baseline \<LLOQ (5 mIU/mL) to post-baseline\>=LLOQ.

    Time frame: Up to 148 Weeks

  5. For HBeAg-positive Patients: Proportion of Subjects With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion at Any Timepoint

    Time frame: Up to 148 weeks

07

Results

Posted Apr 16, 2026

Participant flow

Phase 1 Part1 A-C data results are posted on clinicaltrials.gov in NCT03672188.

Participant flow — Overall Study
MilestoneCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Started15155181813
Completed9155171613
Not completed600120
Withdrew: Physician decision000010
Withdrew: Withdrawal by subject000110
Withdrew: Rolled over to another study600000

Outcome measures

PrimaryNumber of Subjects With Adverse Events as Assessed by CTCAE v5.0
Time frame:
Up to 148 Weeks
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events as Assessed by CTCAE v5.0
ParticipantsCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Number of Subjects With Adverse Events as Assessed by CTCAE v5.09133161713
PrimaryNumber of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings
Time frame:
Up to 148 Weeks
Reported as:
Count of participants · Participants
Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings
ParticipantsCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
ALT Grade 1212212149
ALT Grade 2011222
ALT Grade 3000110
Alkaline phosphatase Grade 1000001
AST Grade 12114141610
AST Grade 2020200
AST Grade 3000010
Bilirubin Grade 1400040
Bilirubin Grade 2010000
Prothrombin, Internalized Normalized Ratio (INR) Grade 1000110
Hemoglobin, anemia (g/DL) grade 1020258
Hemoglobin, anemia (g/DL) grade 2000011
Leukocytes, White blood cell decreased (10^9/L), grade 1363331
Leukocytes, White blood cell decreased (10^9/L), grade 20611397
Leukocytes, White blood cell decreased (10^9/L), grade 3021165
Lymphocytes, Lymphocyte count decreased (10^9/L), grade 1021221
Lymphocytes, Lymphocyte count decreased (10^9/L), grade 20315510
Lymphocytes, Lymphocyte count decreased (10^9/L), grade 3010041
Neutrophils, Neutrophil count decreased (10^9/L), grade 1342411
Neutrophils, Neutrophil count decreased (10^9/L), grade 21811066
Neutrophils, Neutrophil count decreased (10^9/L), grade 30213106
Neutrophils, Neutrophil count decreased (10^9/L), grade 4000010
Platelets, Platelet count decreased (10^9/L), grade 1110310149
Platelets, Platelet count decreased (10^9/L), grade 2001000
Calcium, Hypocalcemia (mg/dL), grade 1020210
Creatinine Clearance (mL/min), grade 1642762
Creatinine Clearance (mL/min), grade 2110001
Gamma Glutamyl Transferase (U/L), grade 1182865
Gamma Glutamyl Transferase (U/L), grade 2010001
Gamma Glutamyl Transferase (U/L), grade 3000010
Glucose (mg/dL), grade 1110110
Lactate Dehydrogenase (U/L), grade 1020652
Potassium, Hyperkalemia (mEq/L), grade 1110101
Potassium, Hypokalemia (mEq/L), grade 2000011
Sodium, Hypernatremia (mEq/L), grade 1000100
SecondaryMean Maximum Reduction of Serum HBsAg at Any Timepoint
Time frame:
Up to 148 Weeks
Reported as:
Mean · Log 10 IU/mL
Mean Maximum Reduction of Serum HBsAg at Any Timepoint
Log 10 IU/mLCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Mean Maximum Reduction of Serum HBsAg at Any Timepoint-1.96 ± 0.29-2.15 ± 0.61-1.73 ± 0.37-2.52 ± 0.82-2.48 ± 1.41-2.99 ± 1.32
SecondaryProportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint
Time frame:
Up to 148 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint
ParticipantsCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint010264
SecondaryProportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months
Time frame:
Up to 148 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months
ParticipantsCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months010142
SecondaryProportion of Subjects With Anti-HBs Seroconversion at Any Timepoint

Anti-HBs seroconversion is defined as Anti-HBs quantitative value changed from baseline \<LLOQ (5 mIU/mL) to post-baseline\>=LLOQ.

Time frame:
Up to 148 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint
ParticipantsCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint983743
SecondaryFor HBeAg-positive Patients: Proportion of Subjects With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion at Any Timepoint
Time frame:
Up to 148 weeks
Reported as:
Count of participants · Participants
For HBeAg-positive Patients: Proportion of Subjects With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion at Any Timepoint
ParticipantsCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
HBeAg loss at any time110331
HBeAg loss with anti-HBe seroconversion at any time000120

Adverse events

Collected over Treatment emergent serious adverse events were defined as AEs reported between Part 1D/2D: Day 1 through Week 27, Part 3D; Day 1 through Week 15, Part 1F: Day 1 through Week 27, Part 2F: Day 1 through Week 51, Part 3F: Day 1 through Week 52.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI0/15 (0%)0/15 (0%)9/15 (60%)
Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI0/15 (0%)0/15 (0%)13/15 (86.7%)
Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI0/5 (0%)0/5 (0%)3/5 (60%)
Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI0/18 (0%)1/18 (5.6%)16/18 (88.9%)
Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI0/18 (0%)1/18 (5.6%)17/18 (94.4%)
Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI0/13 (0%)1/13 (7.7%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
Biliary colicHepatobiliary disorders0/150/150/50/180/181/13
Ankle fractureInjury, poisoning and procedural complications0/150/150/51/180/180/13
ManiaPsychiatric disorders0/150/150/50/181/180/13
Most frequent other events
Showing 10 of 108
Most frequent other events
EventCohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI
COVID-19Infections and infestations0/150/150/50/182/186/13
MyalgiaMusculoskeletal and connective tissue disorders1/151/151/56/183/184/13
FatigueGeneral disorders0/155/151/52/182/181/13
HeadacheNervous system disorders1/153/150/54/183/184/13
Neutrophil count decreasedInvestigations0/151/151/51/184/184/13
Influenza like illnessGeneral disorders0/152/150/52/182/184/13
Injection site erythemaImmune system disorders1/152/151/52/185/182/13
PyrexiaGeneral disorders0/153/150/53/185/182/13
Back painMusculoskeletal and connective tissue disorders3/151/150/50/180/183/13
ArthralgiaMusculoskeletal and connective tissue disorders2/150/151/50/180/180/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
<=18 years0000000
Between 18 and 65 years1515518171383
>=65 years0000101
Age, Continuous
Age, Continuous(Years)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
Mean50.3 ± 8.6246.6 ± 7.8046.2 ± 8.1448.7 ± 5.7945.2 ± 9.3648.5 ± 7.5547.7 ± 7.89
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
Female22143618
Male131341415766
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
Hispanic or Latino0000000
Not Hispanic or Latino1515518181384
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
American Indian or Alaska Native0000000
Asian1213516181377
Native Hawaiian or Other Pacific Islander3201006
Black or African American0000000
White0001001
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
New Zealand63123015
South Korea764104940
Hong Kong11005310
Malaysia0203005
Australia0100001
Thailand12036113
Hepatitis B surface antigen (Log10 IU/mL)
Hepatitis B surface antigen (Log10 IU/mL)(Log10 IU/mL)Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTICohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTICohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTICohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTICohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTICohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTITotal
Mean3.44 ± 0.4473.20 ± 0.6763.39 ± 1.0393.28 ± 0.7262.90 ± 0.8183.35 ± 0.6963.23 ± 0.717
08

Study locations

22 sites
  • Investigative Site
    Birtinya, Queensland 4575, Australia
  • Investigative Site
    Fitzroy, Victoria 3168, Australia
  • Investigative site
    Hong Kong, Hong Kong
  • Investigative Site
    Batu Caves, 68100, Malaysia
  • Investigative Site
    Kajang, 43000, Malaysia
  • Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Investigative Site
    Kuantan, 25100, Malaysia
  • Investigative Site
    Auckland, 1010, New Zealand
  • Investigative Site
    Auckland, 2025, New Zealand
  • Investigative Site
    Busan, 49241, South Korea
  • Investigative Site
    Chuncheon, 24253, South Korea
  • Investigative Site
    Daegu, 41944, South Korea
  • Investigative Site
    Seoul, 03080, South Korea
  • Investigative Site
    Seoul, 05505, South Korea
  • Investigative Site
    Yangsan, 50612, South Korea
  • Investigative Site
    Bangkok, 10330, Thailand
  • Investigative Site
    Bangkok, 10400, Thailand
  • Investigative Site
    Bangkok, 10700, Thailand
  • Investigative Site
    Chiang Mai, 50200, Thailand
  • Investigative Site
    Hat Yai, 90110, Thailand
  • Investigative Site
    Khlong Luang, 12120, Thailand
  • Investigative Site
    Khon Kaen, 40002, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2024, 44 months.

Results were first posted in Apr 2026, 2 years after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 44 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2020
First posted
Jun 2, 2020
StartActual
Jul 3, 2020
Primary completionActual
Mar 25, 2024
CompletionActual
Mar 25, 2024
Results first posted
Apr 16, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04412863
Responsible party
Sponsor
First posted
Jun 2, 2020
Start date
Jul 3, 2020
Primary completion
Mar 25, 2024
Completion
Mar 25, 2024
Results posted
Apr 16, 2026
Last update
Apr 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elebsiran

Start the discussion